What is moxonidine?

Moxonidine: A Centrally Acting Antihypertensive Agent

Moxonidine is a centrally acting antihypertensive medication that selectively activates imidazoline I1 receptors with only minor activity at alpha2-adrenoceptors, but it is NOT recommended for patients with heart failure with reduced ejection fraction (HFrEF) due to increased mortality risk. 1, 2

Mechanism of Action and Pharmacology

• Moxonidine acts centrally to reduce peripheral sympathetic activity by selectively binding to imidazoline I1 receptors in the rostral ventro-lateral medulla, resulting in decreased peripheral vascular resistance 3, 4
• It has 33 times higher affinity for imidazoline I1 receptors compared to alpha2-adrenoceptors, distinguishing it from older centrally acting agents like clonidine 4
• After oral administration, it has high bioavailability (approximately 90%), with a half-life of about 2.5 hours, though its antihypertensive effect lasts longer 4
• It is primarily excreted unchanged in the urine, with minimal biotransformation 4

Clinical Use

• Moxonidine is indicated for the treatment of essential hypertension, typically administered once daily 5, 6
• The usual dosage is 0.4 mg daily, with an initial dose of 0.2 mg/day 5
• It can be used as monotherapy in mild to moderate hypertension or as adjunctive therapy in combination with other antihypertensive agents 3, 6
• It may be particularly beneficial in patients with metabolic syndrome or diabetes mellitus, as it improves metabolic profile in these populations 3, 6

Safety and Adverse Effects

• The most common adverse effects include dry mouth (8-9%), somnolence (5-8%), headache (6%), and dizziness 7
• The incidence and severity of dry mouth and somnolence tend to decrease with continued use over time 7
• It may precipitate or exacerbate depression, bradycardia, and orthostatic hypotension 8
• Sudden cessation of treatment can produce a withdrawal syndrome 8

Important Contraindications and Warnings

• Moxonidine is contraindicated in patients with heart failure with reduced ejection fraction (HFrEF) due to increased mortality risk 1, 2
• European Society of Cardiology guidelines explicitly recommend against using moxonidine to reduce blood pressure in HFrEF patients (Class III recommendation, Level of Evidence B) 1
• It should not be used as a first-line antihypertensive agent and is recommended only when there is intolerance or lack of efficacy of other antihypertensive medications 8, 9

Place in Therapy

• Moxonidine is generally considered a second or third-line antihypertensive agent 8, 9
• It may be particularly useful in patients with:
  • Metabolic syndrome or diabetes mellitus due to favorable metabolic effects 3, 6
  • Hypertension associated with mental stress 6
  • Need for combination therapy in resistant hypertension 5, 6
• It has low potential for drug interactions, making it suitable for patients on multiple medications 3, 7

Monitoring

• Blood pressure should be regularly monitored during treatment 8
• Patients should be assessed for signs of depression, bradycardia, and orthostatic hypotension 8
• Caution is advised when discontinuing therapy to avoid withdrawal symptoms 8